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Aim: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia 
(AML) using biochip array technology. We searched for links between baseline levels and age, hyperleukocytosis, secondary origin 
of AML, resistance to induction therapy with cytarabine and daunorubicin and standard risk stratification according to cytogenetics 
and molecular genetics. Methods: We evaluated the sera of 51 consecutive patients. Serum samples were analyzed by biochip based 
immunoassays on the Evidence Investigator analyzer. T-tests were used for statistical analysis. Results: We found that higher age 
is associated with lower levels of interleukin (IL)-12. Patients with secondary disease were older, had higher levels of EGF and IL-7, 
and lower levels of E-selectin, IL-12 and IL-13. In hyperleukocytosis, the levels of IL-1β, IL-2, TNF-α, VCAM-1, ICAM-1, 
 E-selectin and L-selectin were increased, whereas levels of IFN-γ and MCP-1 were decreased. In patients who failed to achieve 
complete remission after induction therapy, we found lower E-selectin and P-selectin levels. High risk patients had lower levels of IFN-γ. 
Conclusion: Some leukemic cell subpopulations have the ability to produce cytokines that modulate the microenvironment by inducing 
inflammation. This causes endothelial cells to be activated and overexpress adhesion molecules. Hyperleukocytosis and secondary 
origin of the disease are the major factors influencing the cytokine and adhesion molecule profile in newly diagnosed AML patients.
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Acute myeloid leukemia (AML) shows a high degree 
of heterogeneity owing to a variety of mutations and 
the mechanisms involved in leukemogenesis. Cytokines 
and adhesion molecules have been studied as markers 
of immune system activation in various diseases inclu-
ding hematologic malignancies and AML [1, 2]. Cyto-
kines are soluble molecules carrying specific informa-
tion for target cells. Acting through a surface receptor, 
they provide target cells with specific information about 
conditions inside the organism and cause a specific 
response. The response may be, e.g. stimulating and 
activating in the case of inflammation or in the case 
of tissue damage, causing proliferation or apoptosis. 
Under abnormal conditions, this physiological role 
of cytokines is maladaptive. The effect of inflammation 
and altered cytokine signalling on oncogenesis le ading 
to tumor progression, has been documented [3, 4]. 
Blood cells and their marrow-based progenitors are 
exquisitely responsive to their environment, and cyto-
kines are an essential part of it. On binding to cytokine 
receptor, signal transduction pathways (STP) are 
activated and abnormalities in signalling through STP 
are common in AML. Cytokines play a role in leuke-
mogenesis, AML cell persistence, treatment outcome 
and allogeneic transplantation-related phenomena [5]. 
Cytokine-related mechanisms of leukemogenesis, AML 
cell persistence and resistance to chemotherapy are 
complex. Modulation of the cytokine network can disrupt 
signalling pathway activation and overcome the high re-
sistance to treatment. It may also increase the selectivity 
of AML treatment, reduce the overall treatment-related 
toxicity and improve outcomes of AML treatment in all 
age groups of patients. Adhesive interactions also trig-
ger signal transduction pathway activation and this 
prevents the apoptosis of both normal and malignant 
cells. A correlation between expression of defined adhe-
sion molecules and patient outcome has been found for 
several malignant diseases inclu ding AML.
Alterations in the interacting functional network 
of cytokines and adhesion molecules may have 
direct effect on the malignant cells or have indirect 
effect on leukemogenesis through altered functions 
of bone marrow stromal elements [6, 7]. Further 
knowledge gained from multi-analytical determina-
tion of cytokines and adhesion molecules could allow 
better diagnosis and management of hematologic 
malignancies, since cytokines or their receptors may 
also represent a target for specific anticancer therapy 
at the molecular level. Recently, some studies reported 
the possible diagnostic and prognostic use of cytokine 
levels in newly diagnosed AML and myelodysplastic 
syndromes [8–10]. The aim of this study was to evalu-
ate baseline serum levels of cytokines and adhesion 
molecules in patients treated for AML. We evaluated 
changes in cytokine and adhesion molecule levels as-
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sociated with age, hyperleukocytosis and secon dary 
AML origin. Age-related changes were suspected 
in several studies and older patients have often been 
excluded from analyses. On the other hand, age need 
not correlate with biological age or performance sta-
tus. Based on our own experience with good results 
using a curative approach in patients aged 65–70 with 
ECOG performance status 0–2, we decided to search 
for age-related alterations in cytokine and adhesion 
molecule levels. A secondary AML usually evolves 
from previous myelodysplasia or myelofibrosis and 
is more frequent in older patients. Nevertheless, due 
to progress in the treatment of malignancies in younger 
patients (e.g. Hodgkin’s lymphoma, testicular, early 
breast and prostate cancer) and curative treatment, 
some younger patients may also suffer from  secondary 
AML. Hyperleukocytosis may be associated with life 
threatening leukostasis, which is based on capillary 
obstruction by adherent activated myeloblasts in endo-
thelia. There were two reasons why we evaluated hyper-
leukocytosis separately. First, we expected increased 
levels of cytokines directly produced by myeloblasts 
in the blood flow. Second, we anticipated high levels 
of soluble adhesion molecules as leukostasis and ex-
travascular leukemic cell dissemination is exquisitely 
dependent on adhesive interactions [11].
Further, we aimed to determine the prognostic value 
of baseline cytokine and adhesion molecule levels. We di-
vided patients according to standard risk stratification 
based on cytogenetic and molecular genetic examina-
tion into low-risk, intermediate-1 and -2 and high risk 
subgroups to determine whether these subgroups 
differed in cytokine and/or adhesion molecule levels. 
We then took a detailed look at those patients who failed 
to achieve complete remission (CR) after induction 
chemotherapy combining cytarabine and daunorubicin. 
Failure of induction therapy has direct therapeutic conse-
quences. Irrespective of standard prognostic indicators, 
these patients suffered from aggressive disease and 
were reinduced by salvage regimen and allotransplanted 
if a suitable donor was available. Early identification 
of these patients would allow treatment to be more per-
sonalized which is the basic aim of modern medicine.
PATIENTS AND METHODS
Patients. A total of 51 newly diagnosed AML pa-
tients, 19 males and 32 females, mean age 52.5 ± 13.4, 
median 56.2 years, were studied. According to cyto-
genetic and molecular genetic evaluation, 11 patients 
were classified as low risk, 9 — intermediate-1 risk, 
12 — intermediate-2 risk and 19 — high risk disease. 
In 24 patients, normal karyotype was present. Of these, 
5 had NPM-1 mutated (Nucleophosmin-1), 8 patients 
had both NPM-1 and FLT3-ITD (Famosin-like tyrosin 
kinase 3 — internal tandem duplications), 3 patients 
had solely FLT3-ITD and 8 patients had various muta-
tions including CEBPa (CCAT enhancer binding protein 
alpha) and mutations including MLL (Multi-lineage 
leukemia) gene. In 27 patients at least 1 cytogenetic 
abnormality was present. Of these, 4 patients had CBF 
(core binding factor) positive disease, all 4 patients 
with acute promyelocytic leukemia had typical trans-
location present and 6 patients had complex changes 
including 3 or more translocations. According to FAB 
classification, 2 patients had AML M0, 10 patients — 
AML M1, 25 patients — AML M2, 4 patients — AML M3, 
6 patients — AML M4, 3 patients — AML M5 and 1 pa-
tient — AML M7. Hyperleukocytosis requiring urgent 
leukapheresis was present in 12 patients. All patients 
were induced with “3+7” induction chemotherapy 
consisting of cytarabine 100 mg/m2 per day for 7 con-
secutive days and daunorubicin 90 mg/m2 for the first 
3 days of therapy in younger patients. In patients 
aged 65 or more, daunorubicin 45–60 mg/m2 was 
administered. This was followed by consolidation with 
high-dose cytarabine. In those patients who failed 
to achieve CR after “3+7” induction regimen, the sal-
vage chemotherapy “FlAG-Ida” was administered. 
A total of 31 patients who had intermediate or high risk 
disease or failed to achieve CR after “3+7” induction 
regimen had suitable donors for allogeneic stem cell 
transplantation and were able to undergo the proce-
dure. These patients were allotransplanted. The study 
was approved by the local Ethics Committee and all 
patients gave written consent.
Serum collection. Peripheral blood was collected 
in serum separating tubes, immediately transported 
to the laboratory and processed within 2 hours of col-
lection by centrifugation at 1500 rpm × 5 min. All sera 
were collected before leukapheresis, administration 
of hydroxyurea or induction therapy. If specimens 
were not to be analysed immediately, they were stored 
frozen in small aliquots at −20 °C as recommended 
by the Cytokine Array manufacturer. Repeat freeze/
thaw cycles were avoided.
Methods. All analytes were measured by biochip 
array technology using chemiluminescent sandwich 
immunoassays applied to the Evidence Investigator 
Analyzer (Randox Laboratories Ltd., Crumlin, UK). 
The Evidence Investigator Biochip Array technology 
is used to perform simultaneous quantitative detec-
tion of multiple analytes from a single patient sample. 
The core technology is the Randox Biochip, a solid-
state device containing an array of discrete test re-
gions of immobilised antibodies specific to different 
cytokines and growth factors. A sandwich chemilu-
minescent immunoassay is employed for the cytokine 
array. Increased levels of cytokine in a specimen will 
lead to increased binding of antibody labelled with 
horseradish peroxidase (HRP) and thus an increase 
in the chemiluminescent signal emitted. The light 
signal generated from each of the test regions on the 
biochip is detected using digital imaging technology 
and compared to that from a stored calibration curve. 
The concentration of analyte present in the sample 
is calculated from the calibration curve.
We evaluated circulating levels of the following 
17 cytokines and 5 soluble adhesion molecules: in-
terleukins (IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4,  IL-6, 
IL-7, IL-8,  IL-10, IL-12p70, IL-13, IL-23), vascular 
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endothelial growth factor (VEGF), tumor necrosis 
factor-alpha (TNF-α), interferon-gamma (IFN-γ), epi-
dermal growth factor (EGF), monocyte chemotactic 
protein-1 (MCP-1), E-selectin, L-selectin, P-selectin, 
intercellular adhesion molecule-1 (ICAM-1) and vascu-
lar cell adhesion mo lecule-1 (VCAM-1). The results are 
expressed in nanograms per litre (ng/L) for cytokines 
and micrograms per litre (μg/L) for adhesion molecules.
Statistical analysis. Statistical analysis was 
performed with the “Statistica” software using two-
tailed t-tests. The values were expressed as means ± 
standard deviation. Probability values p < 0.05 were 
considered statistically significant.
RESULTS
Age dependent differences. Originally, we ana-
lysed 3 subgroups of patients divided according to age. 
The first subgroup consisted of younger patients aged 
less than 55 years (n = 25), the second subgroup in-
cluded patients aged 55–65 years (n = 11) and the third 
subgroup included patients 65 and older (n = 15). Be-
cause there were no significant differences between 
younger and 55–65 year old patients, we analysed both 
subgroups together against patients older than 65 years.
In patients aged 65 or more, we found a significant 
decrease in IL-12 levels (0.95 ± 1.14 ng/L vs. 4.11 ± 
3.76 ng/L, p = 0.025).
Secondary AML. The group with secondary AML 
consisted of 15 patients with a previous history of MDS 
(myelodysplastic syndrome). Two patients progressed 
to AML from chronic myelomonocytic leukemia and two 
patients from a previous myeloproliferative disorder. They 
were much older than those with primary disease (62.9 ± 
6.7 vs. 46.6 ± 13.3 years, p = 0.00008). In se condary AML, 
we found higher IL-7 (6.13 ± 4.42 ng/L vs. 3.59 ± 1.97 ng/L, 
p = 0.047) and EGF levels (26.64 ± 26.58 μg/L vs. 7.49 ± 
8.05 μg/L; p = 0.004) (Fig. 1). The levels of IL-12 (1.26 ± 
1.46 ng/L vs. 4.32 ± 3.87 ng/L; p = 0.021), IL-13 (2.16 ± 
3.02 ng/L vs. 5.09 ± 4.47 ng/L, p = 0.049) and E-selectin 
(14.85 ± 10.36 μg/L vs. 28.84 ± 18.16 μg/L; p = 0.018) 
were decreased in secondary AML (Fig. 2, 3). The leuko-
cyte counts had a trend to lower counts in the secondary 
AML group which were significant after exclusion of pa-
tients with acute promyelocytic leukemia (15.93 ± 15.99 • 
109/L vs. 53.35 ± 54.44 •  109/L, p = 0.048). We also found 
trends towards higher MCP-1 (246.14 ± 128.35 ng/L vs. 
167.56 ± 101.96 ng/L, p = 0.055) and lower IL-10 levels 
(1.53 ± 1.16 ng/L vs. 4.99 ± 4.86 ng/L, p = 0.075) in se-
condary AML.
H y p e r l e u k o c y t o s i s .  H y p e r l e u k o c y t o -
sis in AML is  defined as a blood count containing 
at least 50 • 109/L  leukocytes. Patients with initial 
hyperleukocytosis (n = 12) had higher levels of IL-1β 
(4.64 ± 4.44 ng/L vs. 0.84 ± 0.49 ng/L, p = 0.0006), 
IL-2 (13.74 ± 15.77 ng/L vs. 3.48 ± 2.85 ng/L, p = 0.009), 
TNF-α (4.79 ± 3.39 ng/L vs. 2.14 ± 1.03 ng/L, p = 0.002) 
(Fig. 4). We also found lower levels of MCP-1 (102.38 ± 
51.29 ng/L vs. 225.89 ± 114.87 ng/L, p = 0.007) and 
IFN-γ (0.42 ± 0.49 ng/L vs. 2.03 ± 1.47 ng/L, p = 0.005), 
in these patients (Fig. 5, 6).
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Fig. 1. Serum levels of EGF and IL-7 in primary and  secondary 
AML. EGF — epidermal growth factor; IL-7 — interleukin 7; 
sec — secondary AML; prim — de novo AML
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Fig. 2. Serum levels of IL-12 and IL-13 in primary and se condary 
AML. IL-12 — interleukin 12; IL-13 — interleukin 13; sec — se-
condary AML; prim — de novo AML
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Fig. 3. Serum levels of E-selectin primary and secondary AML. 
E-SEL — E-selectin; sec — secondary AML; prim — de novo AML
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Fig. 4. Serum levels of IL-2, TNF-α and IL-1β in patients with and 
without hyperleukocytosis. IL-2 — interleukin 2; TNF-α — tumor 
necrosis factor-alpha; IL-1β — interleukin 1β; HLC+ — hyper-
leukocytosis; HLC− — without hyperleukocytosis
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Fig. 5. Serum levels of IFN-γ in patients with and without hyper-
leukocytosis. IFN-γ — interferon-gamma; HLC+ — hyperleuko-
cytosis; HLC− — without hyperleukocytosis
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Fig. 6. Serum levels of MCP-1 in patients with and without 
hyperleukocytosis. MCP1 — monocyte chemotactic protein-1; 
HLC+ — hyperleukocytosis; HLC- — without hyperleukocytosis
Soluble adhesion molecules were greatly increased 
in hyperleukocytosis. We found VCAM-1 (1113.65 ± 
519.71 μg/L vs. 599.59 ± 180.40 μg/L, p = 0.0002), 
ICAM-1 (437.51 ± 177.07 μg/L vs. 296.56 ± 80.99 μg/L, 
p = 0.004) and E-selectin (40.65 ± 13.90 μg/L vs. 
18.39 ± 14.11 μg/L, p = 0.0006) (Fig. 7, 8). The levels 
of L-selectin were at the upper limit of the Array sen-
sitivity in the vast majority of patients with hyperleuko-
cytosis, similar to several patients without hyperleu-
kocytosis. Hence, the results are probably affected. 
However, we measured increased levels of L-selectin 
(3262.18 ± 265.10 μg/L vs. 2307.96 ± 1010.81 μg/L, 
p  = 0.006) in hyperleukocytosis (data not shown).
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Fig. 7. Serum levels of VCAM-1 and ICAM-1 in patients with 
and without hyperleukocytosis. VCAM1 — vascular cell adhe-
sion molecule-1; ICAM1 — intercellular adhesion molecule-1; 
HLC+ — hyperleukocytosis; HLC− — without hyperleukocytosis
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Fig. 8. Serum levels of E-selectin in patients with and without 
hyperleukocytosis. E-SEL — E-selectin; HLC+ — hyperleukocy-
tosis; HLC− — without hyperleukocytosis
Resistance to induction therapy. Those who had 
not achieved CR after induction chemotherapy and were 
reinduced with the salvage regimen (n = 11), had lower 
E-selectin (11.63 ± 7.34 μg/L vs. 26.93 ± 17.81 μg/L, 
p = 0.028) and P-selectin levels (76.19 ± 23.29 μg/L vs. 
136.04 ± 64.74 μg/L, p = 0.022). On the other hand, 
those who failed to achieve CR had significantly higher 
CRP (C-reactive protein) levels (63.4 ± 54.8 mg/L vs. 
27.4 ± 26.0 mg/L, p = 0.017) (Fig. 9, 10).
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Fig. 9. Serum E-selectin and P-selectin levels in patients who 
failed to reach CR after induction therapy. E-SEL —  E-selectin; 
P-SEL — P-selectin; no CR — failed to reach CR after induction 
therapy; CR — attained CR after induction therapy
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Fig. 10. Serum CRP levels in patients who failed to reach CR after 
induction therapy. CRP — C-reactive protein; no CR — failed 
to reach CR after induction therapy; CR — attained CR after 
induction therapy
Risk stratification and cytokine levels. Fi-
nally, we analysed subgroups based on cytogenetic 
and molecular genetic risk stratification. There was 
no significant difference between the groups but when 
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we ana lysed the high risk subgroup (n = 19) against 
the 3 other prognostic subgroups (n = 32) we found 
decreased IFN-γ levels (1.02 ± 1.11 ng/L vs. 2.03 ± 
1.49 ng/L, p = 0.049) in high risk patients (Fig. 11). 
No other significant differences were found in the levels 
of other evaluated cytokines or adhesion molecules 
in any analysis.
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Fig. 11. Serum levels of IFN-γ in high risk patients. IFN-γ — 
interferon-gamma; HR+ — high risk; HR− — other risk
DISCUSSION
Altered levels of cytokines and adhesion molecules 
have been found in many pathological states and have 
been linked to autoimmune diseases, allergies and 
cancer, including AML [3–5, 12–14]. Cytokines and ad-
hesion molecules form an unique interacting functional 
network. This led us to study both systems together.
Our results are in agreement with the general 
finding that patients with secondary AML are usually 
older than those with primary disease. The decrease 
in  IL-12 levels found in elderly patients is probably attri-
buted to se condary AML. We venture to suggest that 
the origin of AML is a more important factor for cytokine 
and adhesion molecule levels than age per se. The finding 
of lower IL-13 levels in secondary AML is in agreement with 
previous results, where MDS patients had lower IL-13 le-
vels than AML [9]. Further, the trend to lower IL-10 levels 
in secondary disease may explain the recently published 
negative prognostic impact of low IL-10 levels [10].
We found evidence that hyperleukocytosis has 
direct impact on levels of several cytokines and 
soluble adhesion molecules. We think that increased 
levels of IL-1 beta and IL-2 reflect production of these 
cytokines by myeloblasts in the blood circulation. 
The IL-1, IL-2 and b-chemokine of the CC subgroup 
CCL-3 (CC-ligand-3) were shown to stimulate leu-
kemic cell proliferation. IL-1β is the predominant 
secreted form of IL-1 [15]. Possibly, the myeloblasts 
trigger autocrine inflammatory loops enhancing their 
own proliferation which causes hyperleukocytosis 
and TNF-α inflammatory overproduction. E-selectin 
is expressed by endothelia. Its expression is regulated 
on the transcriptional level and is induced by TNF-α, 
IL-1 and oncostatin M. In response to myeloid growth 
factors, endothelia increase expression of E-selectin, 
VCAM-1 and ICAM-1 and promote augmented leu-
kocyte adhesion in a p38 MAPK dependent manner. 
Soluble adhesion molecules originate from proteolytic 
cleavage of surface-expressed adhesion molecules. 
In lymphoma-bearing mice, the lymphoma cells are 
the major source of soluble L-selectins [16–18]. 
We speculate that in hyperleukocytosis the soluble 
 L-selectin mo lecules originate from myeloblasts, 
whereas increased levels of VCAM-1, ICAM-1 and E-se-
lectin originate from inflammatory activated endothelia.
In those patients who failed to reach CR after “3+7” 
induction therapy, the levels of E- and P- selectins were 
found to be decreased. Further, the higher CRP level 
in these patients indicates an activated inflammatory 
response. It is unclear whether these high CRP levels 
were caused by systemic infection or reflect the activity 
of highly aggressive disease. From previous studies, 
we know that cytokine levels do not correlate with in-
fection [9], but we lacked data for adhesion molecules. 
Decreased levels of selectin adhesion molecules seem 
to be in contradiction with the findings in hyperleukocy-
tosis, as one would expect inferior outcomes in patients 
with hyperleukocytosis which was found to increase 
 E-selectin levels. What we have to take into account 
is the ability of leukemic blasts to bind to soluble ad-
hesion molecules. In KG-1, AML cell line interactions 
with both P- and E- selectins under flow have been 
documented. Upon adhesion of myeloblasts to se-
lectin adhesion molecules, the adherent myeloblasts 
may sustain toxic concentrations of chemotherapeutic 
agents and thus be rescued from death [19, 20]. This 
mechanism suggests how adhesive interactions pro-
tect AML cells during chemotherapy. For this reason, 
possibly, the levels of E- and P-selectins in patients 
resistant to induction chemotherapy were low be-
cause the soluble adhesion molecules were attached 
to leukemic blasts and thus not measured. The origin 
of the MCP-1 and IFN-γ decrease remains unclear and 
is worth further investigation.
The risk stratification of AML is exactly defined 
by cytogenetics and molecular genetics. We  attemp ted 
to match standard risk stratification with specific 
alterations in cytokine or adhesion molecule levels. 
We found decreased IFN-γ in the high risk subgroup 
which was not described previously [9]. On critical 
reappraisal however, the high risk subgroup in our 
analysis included both patients with normal karyotype 
and those with high risk molecular genetics, the same 
as patients with high risk cytogenetics and complex 
karyotype. Thus, the high risk group was not homo-
genous and this may have been reflected in the results.
Based on analysis of patient sera and healthy 
blood donors as a non-leukemic control, we previ-
ously reported that changes in cytokine and adhesion 
molecule levels are related to disease activity [21]. 
Our results indicate that serum levels of specific 
cytokines and adhesion molecules are significantly 
altered in AML patients and this enables us to further 
understand the mechanisms of disease progression 
and resistance to treatment. We highlight the impor-
tance of E- and P-selectin levels in AML and to the best 
of our knowledge this is the first published evidence 
in vivo. Further studies in a larger number of patients 
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will be needed to confirm our data and define the po-
tential role of these and additional markers in the risk 
stratification and therapy of AML patients.
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